On July 23, 2026, in London and New York, OKYO Pharma Limited (Nasdaq: OKYO) disclosed that their CEO, Robert J. Dempsey, acquired 15,000 of the company's ordinary shares on NASDAQ at a rate of $1.54 per share. OKYO Pharma is a clinical-stage biopharmaceutical firm focused on developing potential solutions for neuropathic corneal pain (NCP) and anterior segment eye conditions.